When
my father called me with the news that he had cancer, I was devastated. He controlled his emotions far better than I,
proving himself the eternal optimist.
His prostate cancer was in the beginning stages and he chose
radiation
therapy instead of surgery. I would get
constant phone updates from him. One day
he told me that the pills he was taking were worth $1000 dollars a day. Thank goodness the Canadian health care
system was footing the bill. The radiation
therapy was hard on him, some days leaving him feeling him more ill
than the
cancer itself did.
With
luck and a lot of prayer he pulled through.
If only I’d known then what I know now, I might have saved
him a lot of
pain and suffering.
Along
with all of the documented beneficial powers of Melatonin you have read
about
so far, it has another unique feature:
It
can stop the development and spread of cancer.
Scientists all over the world have come to realize that the circadian light and dark cycle seems to have an affect on the ability of the human body to prevent cancer. The human body creates more Melatonin in darkness, less when there is light. There has been a discovery that in arctic populations who spend months in total darkness, the incidence of cancer is considerably lower than in industrialized areas.[1] It has also been noted that people who are totally blind show 31% less incidence of cancer than sighted people.[2]
Conversely, it has been found that people who continually work the night shift have a higher incidence of cancer.[3]
Our mothers told us that a good night sleep is the body’s way of repairing itself. Research has finally proven what our mothers have known for years. Melatonin is created at night by the pineal gland. Melatonin is crucial for the body’s fight against cancer and other forms of physical break down. Scientists have found that people with tumor causing cancers have lower Melatonin levels than healthy subjects.[4] It may well be the Melatonin that is reducing the onset of cancer. Rats that have had their pineal glands removed show a dramatic increase in cancer cell development, while treating them with Melatonin reduced the cancer occurrence.[5]
While some studies point to Melatonin creating a decrease in all tumor causing cancers, many focus on two cancers that Melatonin is extremely effective at preventing and treating: prostate and breast cancer. In my research, the only cancer that Melatonin doesn’t seem to be effective against is Leukemia. Scientific experimentation at the University of McGill in Montreal, Canada has found that the herbal supplement Echinacea Purpurea has a profound effect in helping the body to overcome Leukemia.[6] Echinacea is yet another substance ignored by the medical community possibly due to the fact that no drug company can profit from it.
As men age their prostate glands becomes more likely to develop cancerous cells, which can become life threatening malignant tumors. Scientists have shown that the Melatonin levels in men drop considerably as they enter the later stages of life.[7] Men who developed prostate cancers show a below average production level of Melatonin. Research suggests that a reduction in Melatonin may be related to the development and growth of prostate cancer.[8]
To determine the prostate cancer threat in men, doctors test the prostate-specific antigen (PSA) levels in the blood. Elevated levels of the PSA are sometimes the individual’s first warning that they may have a prostate condition. Melatonin has been found to reduce the PSA count in the blood of subjects with prostate tumors. Melatonin was also found to have anti-tumor properties.[9]
Not only does Melatonin seem to stop the proliferation of androgen-specific cancer cells and metastatic tumor growth in the Prostate, but it may also reverse the cancer itself.[10]
Every year, almost 200,000 new cases of prostate cancer are diagnosed in the United States and Canada. This form of cancer is common in North America and Western Europe, but rare in Africa, South America and Asia. This fact makes me consider that this may be yet another disease that may have a link to our westernized diet and lifestyle. Every year, hundreds of thousands of men undergo painful prostate surgery and radiation treatments. In the process they use billions of dollars worth of hospitalization and medication.
Simply adding Melatonin to your vitamin regimen could reduce the cancerous activity in your prostate, or, better yet, reduce your chance of ever getting cancer at all. That would, however, deny the drug companies and the medical establishment their right to profit from your pain.
Would that be so wrong?
Men aren’t alone in benefiting from the anti-cancer effects of Melatonin. Women as well can reap its benefits. Blind women, show a marked decrease in breast cancer, while women who work shift work and sleep opposite to normal darkness cycles show an increased susceptibility to breast cancer.[11] Melatonin is the main hormone whose production is directly dependent on light/dark circadian rhythms.
This
has led many scientists to come to the conclusion that Melatonin may be
useful
in breast cancer therapy.[12]
Over 200,000 women in United States and Canada are diagnosed with breast cancer each year. These women will have to choose between the surgically invasive lumpectomy, mastectomy, chemo, or radiation therapies. Unfortunately, for over 40,000 of these women the disease will prove fatal.
Research has found
that
Melatonin actually suppresses the growth of existing tumor cells in
women.[13] Further research on breast cancer shows that
tumors can be reduced in size and number with the addition of Melatonin
to the
diet.[14]
The
American Cancer Society’s Webpage at ‘www.cancer.org’
has hormone therapies
listed under its heading of Suggestions for Breast Cancer Treatment. I read the article with interest hoping to
see mention of the natural hormone, Melatonin.
Instead of the Melatonin that studies have shown can treat
breast
cancer, the society lists the following artificially created and
patented
prescription drugs: Tamoxifen (sold as Nolvadex) and Raloxifene (an
estrogen
blocker sold as Evista).
Not
only do these drugs have dangerous side effects, but they are an
expensive
treatment as well.
A
visit to ‘www.drugstore.com’ gives us an idea of just how
much the
pharmaceutical companies are charging for the treatment sponsored by
the
American Cancer Society.
Nolvadex
suggested dosage: 20-40mg daily
30 day supply @ 40 mgs
daily: $214.76
Daily dosage price: $7.16
Evista
suggested dosage: one 60 mg
tablet daily
30 day supply @ 60 mgs
daily: $70.99
Daily dosage price: $2.37
Taken
long term, these drugs are far from inexpensive. But
if they save a life from cancer, then any
price is worth it right? But what if there
is actually little evidence that these two drugs are actually effective
at
treating breast cancer?
In
2002, the American Society of Clinical Oncology gathered to review the
evidence
of Tamoxifen and Raloxifene in treating cancer.
Their report found that data reviewed “do not as
yet suggest
that tamoxifen provides an overall health benefit or increases
survival.” They further went on
to say, “use of
tamoxifen combined with hormone replacement therapy or use of
raloxifene … to
lower the risk of developing breast cancer is not recommended outside
of a
clinical trial setting.”[15]
Not
recommended outside of a clinical setting?
Yet these are the prescriptions of choice given by doctors to
breast
Cancer patients all over North America.
These are the drugs supported by the American Cancer Society.
If
a group of expert cancer physicians does not fully validate and support
the use
of these drugs for breast cancer treatment, why are women being told to
take
them?
Money.
Those
snake oil salesmen in the doctor’s office are doing one terrific
job. Doctors today are so overworked by
their
caseloads, how can anyone expect them to keep up on the last
pharmaceutical
discoveries and published research.
Instead they may listen to the recommendations of the American
Cancer
Society, who very well might receive funding directly from
pharmaceutical
companies. They may also rely on the
research proposed to them in a 5-minute pitch from a professional
looking
salesman extolling the virtues of their soundly patented drug.
Can
you trust a salesman to always tell the truth?
Your health is not a used car.
[1] Erren,
TC.
Piekarski, C. “Does winter darkness
in
the Artic protect against cancer? The
melatonin hypothesis revisited.” Med
Hypotheses 1999 Jul;53(1):1-5.
[2]
Feychting, M. Osterlund, B. Ahlbom, A.
“Reduced cancer
incidence among the blind.” Epidemiology
1998 Sep;9(5):490-4.
[3] Anisimov, VN. “The light-dark regimen and cancer development.” Neuroendocrinol Lett 2002 Jul;23 Suppl 2:28-36.
[4] Bartsch,
C.
Bartsch, H. “Melatonin in cancer patients and in
tumor-bearing
animals.” Adv Exp Med Biol 1999;467:247-64.
[5]
Tamarkin, L. Cohen, M. Roselle, D.
Reichert, C.
Lippman, M. Chabner, B. “Melatonin
inhibition and pinealectomy enhancement of
7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat.” Cancer Res 1981 Nov;41(11 Pt
1):4432-6.
[6] Currier,
NL.
Miller, SC. “Echinacea purpurea and melatonin
augment
natural-killer cells in leukemic mice and prolong life span.” J Altern Complement Med 2001
Jun;7(3):241-51.
[7] Schulman, C. Lunenfeld, B. “The ageing male.” World J Urol 2002 May;20(1):4-10.
[8]
Bartsch, C. Bartsch, H. Fluchter, SH.
Attanasio, A.
Gupta, D. “Evidence for modulation
of
melatonin secretion in men with benign and malignant tumors of the
prostate:
relationship with the pituitary hormones.”
J Pineal Res 1985;2(2):121-32.
[9]
Xi, SC. Siu, SW. Fong, SW. Shiu, SY.
“Inhibition of androgen-sensitive
LNCaP prostate cancer growth in vivo by melatonin: association of
antiproliferative action of the pineal hormone with mt1 receptor
protein
expression.” Prostate 2001
Jan
1;46(1):52-61.
[10]
Lissoni, P. Cazzaniga, M. Tancini, G.
Scardino,
E. Musci, R. Barni, S. Maffezzini, M. Meroni, T. Rocco, F. Conti, A.
Maestroni,
G. “Reversal of clinical resistance
to
LHRH analogue in metastatic prostate cancer by the pineal hormone
melatonin:
efficacy of LHRH analogue plus melatonin in patients progressing on
LHRH
analogue alone.” Eur Urol
1997;31(2):178-81.
[11] Glickman,
G.
Levin, R. Brainard, GC. “Ocular
input
for human melatonin regulation: relevance to breast cancer.” Neuroendocrinol Lett 2002 Jul;23
Suppl 2:17-22.
[12]
Dillon, DC. Easley, SE. Asch, BB. Cheney,
RT.
Brydon, L. Jockers, R. Winston, JS. Brooks, JS. Hurd, T. Asch, HL. “Differential expression of
high-affinity
melatonin receptors (MT1) in normal and malignant human breast
tissue.” Am J Clin Pathol
2002
Sep;118(3):451-8.
[13]
Yuan, L. Collins, AR. Dai, J. Dubocovich,
ML.
Hill, SM. “MT(1) melatonin receptor overexpression enhances the
growth
suppressive effect of melatonin in human breast cancer cells.” Mol Cell Endocrinol 2002 Jun
28;192(1-2):147-56.
[14]
Anisimov, VN. Alimova, IN. Baturin, DA.
Popovich,
IG. Zabezhinski, MA. Manton, KG. Semenchenko, AV. Yashin, AI. “The effect of melatonin treatment
regimen on
mammary adenocarcinoma development in HER-2/neu transgenic mice.”
Int J
Cancer 2003 Jan 20;103(3):300-5.
[15]
Chlebowski, RT. Col, N. Winer, EP.
Collyar, DE.
Cummings, SR. Vogel, VG. 3rd, Burstein, HJ. Eisen, A. Lipkus, I.
Pfister, DG;
American Society of Clinical Oncology Breast Cancer Technology
Assessment
Working Group. “American Society of
Clinical Oncology technology assessment of pharmacologic interventions
for
breast cancer risk reduction including tamoxifen, raloxifene, and
aromatase
inhibition.” Clin Oncol
2002 Aug
1;20(15):3328-43.